Trial · NCT00360412
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 0 | -0.78 | Standard Deviation 2.158 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 0 | -0.85 | Standard Deviation 2.498 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 4 | -1.37 | Standard Deviation 2.483 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 4 | -1.16 | Standard Deviation 2.632 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 8 | -1.21 | Standard Deviation 2.400 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 8 | -1.19 | Standard Deviation 2.568 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 20 | -1.11 | Standard Deviation 2.537 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 20 | -1.34 | Standard Deviation 2.694 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 32 | -0.91 | Standard Deviation 2.663 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 32 | -1.38 | Standard Deviation 2.676 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 44 | -0.73 | Standard Deviation 2.371 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 44 | -1.44 | Standard Deviation 2.470 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 56 | -0.64 | Standard Deviation 2.607 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 56 | -0.78 | Standard Deviation 2.010 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | week 68 | -0.92 | Standard Deviation 2.239 | Hours |
| Mean Change From Baseline in Total Daily OFF Time (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | week 68 | -1.05 | Standard Deviation 1.820 | Hours |
| Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 0 | 0.73 | Standard Deviation 2.389 | Hours |
| Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 0 | 0.65 | Standard Deviation 2.567 | Hours |
| Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study | Perampanel (Placebo During Core Study) | Week 4 | 1.02 | Standard Deviation 2.664 | Hours |
| Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) During Open-label Extension Study | Perampanel (Perampanel 2 mg or 4 mg During Core Study) | Week 4 | 0.98 | Standard Deviation 2.665 | Hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00360412/results